Adaptive Biotechnologies (NASDAQ:ADPT) reported Q4 EPS of ($0.28), $0.07 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $55.2 million versus the consensus estimate of $55.28 million.
Adaptive Biotechnologies (NASDAQ:ADPT) reported Q4 EPS of ($0.28), $0.07 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $55.2 million versus the consensus estimate of $55.28 million.